Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Receivables - Accured (2023 - 2024)

Roivant Sciences (ROIV) has disclosed Receivables - Accured for 2 consecutive years, with $23.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Receivables - Accured rose 22.68% year-over-year to $23.2 million, compared with a TTM value of $23.2 million through Dec 2024, up 22.68%, and an annual FY2024 reading of $23.2 million, up 22.68% over the prior year.
  • Receivables - Accured was $23.2 million for Q4 2024 at Roivant Sciences, up from $13.9 million in the prior quarter.
  • Across five years, Receivables - Accured topped out at $27.4 million in Q1 2024 and bottomed at $4.9 million in Q1 2023.